how did we get here
Highlights and milestones
Completed the acquisition of F-star Therapeutics –March 2023
On 9th March 2023, following regulatory approvals, invoX has completed the acquisition of F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy. The transaction significantly strengthens invoX’s pharmaceutical business, accelerating the build of a pipeline with a core focus on oncology and respiratory therapeutics, as well as bringing a world class clinical development team that will be leveraged to deliver to patients globally.
invoX Pharma Announced Definitive Agreement to Acquire F-star Therapeutics, Inc. –June 2022
invoX has signed a merger agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at approximately $161m.
Karolinska Development concluded a rights issue with invoX increasing its shareholding to 47.67% –February 2022
Karolinska Development concluded a rights issue, the proceeds will finance the continued development of existing investments, new investments, and general corporate purposes.
Sino Biopharmaceutical transferred its holding in Karolinska Development –October 2021
Sino Biopharmaceutical transferred its holding in Karolinska Development (KD) to the wholly owned subsidiary invoX Pharma Ltd. KD is an early-stage, publicly-listed Nordic venture capital firm focusing on investiments in innovative life sciences companies.
Acquired a majority stake in pHion Therapeutics –June 2021
pHion is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response.
Acquired 100% of the shareholding in Softhale NV –March 2021
Softhale is a privately held Belgium-based respiratory company focused on the development of pharmaceutical products with superior clinical performance based upon differentiated technology delivered by our next generation Soft Mist Inhalation (SMI) device to the lungs.
invoX was established –March 2021
invoX is a wholly-owned subsidiary of Sino Biopharmaceutical Ltd,. invoX focuses on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.